Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/630 
Authors: 
Year of Publication: 
1992
Citation: 
[Publisher:] Centre for Economic Policy Research (CEPR) [Place:] London [Year:] 1992
Series/Report no.: 
CEPR Discussion Paper Series, Centre for Economic Policy Research (CEPR), London No. 675
Publisher: 
Centre for Economic Policy Research (CEPR), London
Abstract: 
This paper develops a framework within which the impact of the proposed initiatives of the European Commission for creating an internal market for pharmaceuticals can be analysed. In a model of third-degree price discrimination, arbitrage between two markets and price controls through governments in one market are introduced. The effects of easier arbitrage opportunities, i.e. lower arbitrage costs, on the prices in the two markets are analysed. Also, the impact of a reduction in price controls in the low-priced markets as well as their combined effects are characterized. The welfare effects of the Internal Market in pharmaceuticals are ambiguous, since a movement from segmented and price-controlled markets towards integrated markets does not lead to a first- or second-best solution.
JEL: 
O43
O60
F13
F15
Document Type: 
Working Paper
Document Version: 
Digitized Version

Files in This Item:
File
Size





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.